SCHEMBL24258033

SCHEMBL24258033

O=c1ccc(-c2cnn(Cc3ccc(Cl)c(Cl)c3)c2)c[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.55
KMT2A Q03164 2/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
GRIN2B Q13224 3/20 0.48
CREBBP Q92793 4/20 0.44
BACE1 P56817 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258041 0.77 KCNH2 (0.56) KCNH2GRIN2BHTTMKNK1MKNK2
SCHEMBL3591944 0.71 HSD17B10 (0.61) KMT2ATSHRMAPK1HSD17B10BACE1
SCHEMBL13508771 0.71 KCNH2 (1.00) KCNH2KMT2AL3MBTL1MAPTHTT
SCHEMBL24258034 0.71 KCNH2 (0.69) KCNH2KMT2AHTTNPSR1SMN1; SMN2
SCHEMBL20532580 0.71 CREBBP (0.69) CREBBPL3MBTL1
SCHEMBL13692159 0.70 KMT2A (0.68) KCNH2KMT2ATSHRMAPK1HSD17B10
SCHEMBL3612964 0.70 KMT2A (0.68) KMT2ATSHRMAPK1HSD17B10BACE1
SCHEMBL18235823 0.70 KMT2A (0.62) KMT2ATSHRMAPK1HSD17B10BACE1
SCHEMBL26004954 0.69 KMT2A (0.51) KCNH2KMT2ATSHRMAPK1HSD17B10
SCHEMBL18235821 0.69 KMT2A (0.66) KCNH2KMT2ATSHRMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 KCNH2 4853/4885KMT2A 1212/4885TSHR 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.